EPICEPT ANNOUNCES PUBLICATION OF CEPLENE DATA

A A

EpiCept has announced that the results of a randomized, multicenter Phase III clinical study of 320 patients with advanced myeloid leukemia (AML), in which the drug Ceplene met its primary endpoint of increased leukemia-free survival among patients in remission, have been published in the journal Blood.

Based on the findings from this study, the company plans to file a market authorization application with the European Agency for the Evaluation of Medicinal Products for approval of Ceplene in Europe.